Cargando…
AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures
Can you imagine a disease in which intake of an excess amount of sugars or carbohydrates causes hyperammonemia? It is hard to imagine the intake causing hyperammonemia. AGC2 or citrin deficiency shows their symptoms following sugar/carbohydrates intake excess and this disease is now known as a pan-e...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465890/ https://www.ncbi.nlm.nih.gov/pubmed/32722104 http://dx.doi.org/10.3390/biom10081100 |
_version_ | 1783577685931327488 |
---|---|
author | Saheki, Takeyori Moriyama, Mitsuaki Funahashi, Aki Kuroda, Eishi |
author_facet | Saheki, Takeyori Moriyama, Mitsuaki Funahashi, Aki Kuroda, Eishi |
author_sort | Saheki, Takeyori |
collection | PubMed |
description | Can you imagine a disease in which intake of an excess amount of sugars or carbohydrates causes hyperammonemia? It is hard to imagine the intake causing hyperammonemia. AGC2 or citrin deficiency shows their symptoms following sugar/carbohydrates intake excess and this disease is now known as a pan-ethnic disease. AGC2 (aspartate glutamate carrier 2) or citrin is a mitochondrial transporter which transports aspartate (Asp) from mitochondria to cytosol in exchange with glutamate (Glu) and H(+). Asp is originally supplied from mitochondria to cytosol where it is necessary for synthesis of proteins, nucleotides, and urea. In cytosol, Asp can be synthesized from oxaloacetate and Glu by cytosolic Asp aminotransferase, but oxaloacetate formation is limited by the amount of NAD(+). This means an increase in NADH causes suppression of Asp formation in the cytosol. Metabolism of carbohydrates and other substances which produce cytosolic NADH such as alcohol and glycerol suppress oxaloacetate formation. It is forced under citrin deficiency since citrin is a member of malate/Asp shuttle. In this review, we will describe history of identification of the SLC25A13 gene as the causative gene for adult-onset type II citrullinemia (CTLN2), a type of citrin deficiency, pathophysiology of citrin deficiency together with animal models and possible treatments for citrin deficiency newly developing. |
format | Online Article Text |
id | pubmed-7465890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74658902020-09-04 AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures Saheki, Takeyori Moriyama, Mitsuaki Funahashi, Aki Kuroda, Eishi Biomolecules Review Can you imagine a disease in which intake of an excess amount of sugars or carbohydrates causes hyperammonemia? It is hard to imagine the intake causing hyperammonemia. AGC2 or citrin deficiency shows their symptoms following sugar/carbohydrates intake excess and this disease is now known as a pan-ethnic disease. AGC2 (aspartate glutamate carrier 2) or citrin is a mitochondrial transporter which transports aspartate (Asp) from mitochondria to cytosol in exchange with glutamate (Glu) and H(+). Asp is originally supplied from mitochondria to cytosol where it is necessary for synthesis of proteins, nucleotides, and urea. In cytosol, Asp can be synthesized from oxaloacetate and Glu by cytosolic Asp aminotransferase, but oxaloacetate formation is limited by the amount of NAD(+). This means an increase in NADH causes suppression of Asp formation in the cytosol. Metabolism of carbohydrates and other substances which produce cytosolic NADH such as alcohol and glycerol suppress oxaloacetate formation. It is forced under citrin deficiency since citrin is a member of malate/Asp shuttle. In this review, we will describe history of identification of the SLC25A13 gene as the causative gene for adult-onset type II citrullinemia (CTLN2), a type of citrin deficiency, pathophysiology of citrin deficiency together with animal models and possible treatments for citrin deficiency newly developing. MDPI 2020-07-24 /pmc/articles/PMC7465890/ /pubmed/32722104 http://dx.doi.org/10.3390/biom10081100 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saheki, Takeyori Moriyama, Mitsuaki Funahashi, Aki Kuroda, Eishi AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures |
title | AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures |
title_full | AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures |
title_fullStr | AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures |
title_full_unstemmed | AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures |
title_short | AGC2 (Citrin) Deficiency—From Recognition of the Disease till Construction of Therapeutic Procedures |
title_sort | agc2 (citrin) deficiency—from recognition of the disease till construction of therapeutic procedures |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465890/ https://www.ncbi.nlm.nih.gov/pubmed/32722104 http://dx.doi.org/10.3390/biom10081100 |
work_keys_str_mv | AT sahekitakeyori agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures AT moriyamamitsuaki agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures AT funahashiaki agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures AT kurodaeishi agc2citrindeficiencyfromrecognitionofthediseasetillconstructionoftherapeuticprocedures |